COVID-19 Vaccines – an optometrist’s guide
28 October 2020
Acuity digital
As the pandemic continues to affect people’s lives across the UK, interest in a viable vaccine is growing. The College's Director of Research, Michael Bowen looks at what guidance optometrists can offer patients on potential COVID-19 vaccines.
With the continued disruption the pandemic is wreaking in people’s lives, speculation and interest in a potential vaccine is growing among the general public. Optometry, along with all other health professions, has a greater interest than most, and patients may look to optometrists in their role as clinicians for information on an upcoming vaccine. What can you tell your patients about potential vaccines?
There are 166 potential COVID-19 vaccines to date which are in pre-clinical or clinical trials (Lurie et al, 2020), and at least 27 of these are in phase 1 or 2 trials. The Oxford / AstraZeneca vaccine is further along in phase 2b/3 (efficacy trial in humans/ evaluation trial in humans respectively). The table below, taken from a World Health Organisation (WHO) report published very recently, shows the leading vaccine trials, and gives brief details of the vaccines and the current status of the trial.
Not already a member of the College?
Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
Related further reading
Prime Minister, Keir Starmer, today announced he is bringing the management of the NHS back into democratic control by abolishing NHS England.
We have issued a statement about the decision to end glaucoma and cataracts enhanced eye care services in Hampshire and Isle of Wight at the end of this month.
The updated guidance will support optometry professionals in maintaining and enhancing standards of patient care.